Summit Therapeutics PLC (LON:SUMM) was up 7% during mid-day trading on Wednesday . The company traded as high as GBX 23 ($0.30) and last traded at GBX 23 ($0.30). Approximately 270,000 shares changed hands during mid-day trading, an increase of 680% from the average daily volume of 34,608 shares. The stock had previously closed at GBX 21.50 ($0.28).

In other news, insider Leopoldo Zambeletti sold 11,358 shares of the firm’s stock in a transaction that occurred on Wednesday, October 24th. The shares were sold at an average price of GBX 28 ($0.37), for a total value of £3,180.24 ($4,155.55).

COPYRIGHT VIOLATION WARNING: “Summit Therapeutics (SUMM) Trading Up 7%” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at

About Summit Therapeutics (LON:SUMM)

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Further Reading: Understanding debt-to-equity ratio in fundamental analysis

Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with's FREE daily email newsletter.